Products for Research Use Only

Nevirapine-d3

CAT: 0804-HY-10570S1-01Size: 500 µgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-10570S1-01Size:500 µg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Nevirapine-d3 (BI-RG 587-d3) is the deuterium labeled Nevirapine. Nevirapine is a non-nucleoside inhibitor of HIV-1 reverse transcriptase used to treat and prevent HIV/AIDS; with a Ki of 270 μM[1].
CAS Number
1051419-24-9
UNSPSC
12352005
Target
HIV; Isotope-Labeled Compounds; Reverse Transcriptase
Type
Isotope-Labeled Compounds
Related Pathways
Anti-infection; Others
Applications
COVID-19-anti-virus
Field of Research
Infection; Cancer
Solubility
10 mM in DMSO
Smiles
C(C1=C2C(N(C=3C(C(=O)N2)=CC=CN3)C4CC4)=NC=C1)([2H])([2H])[2H]
Molecular Formula
C15H11D3N4O
Molecular Weight
269.32
References & Citations
[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Erickson DA, et al. Characterization of the in vitro biotransformation of the HIV-1 reverse transcriptase inhibitornevirapine by human hepatic cytochromes P-450. Drug Metab Dispos. 1999 Dec;27 (12) :1488-95.|[3]Dong JJ, et al. In vitro evaluation of the therapeutic potential of nevirapine in treatment of human thyroid anaplastic carcinoma. Mol Cell Endocrinol. 2013 May 6;370 (1-2) :113-8.|[4]Merluzzi VJ, et al. Inhibition of HIV-1 replication by a nonnucleoside reverse transcriptase inhibitor. Science. 1990 Dec 7;250 (4986) :1411-3.|[5]Riska PS, et al. Biotransformation of nevirapine, a non-nucleoside HIV-1 reverse transcriptase inhibitor, in mice, rats, rabbits, dogs, monkeys, and chimpanzees. Drug Metab Dispos. 1999 Dec;27 (12) :1434-47.|[6]Onasanwo SA, et al. Evaluation of anti-ulcerogenic and ulcer-healing activities of nevirapine in rats. Afr J Med Med Sci. 2015 Sep;44 (3) :251-9.
Shipping Conditions
Room temperature
Scientific Category
Isotope-Labeled Compounds
Clinical Information
No Development Reported